AB Science specializes in research, development, and sales of kinase protein inhibitors (KPI), therapeutic drugs used in treating cancerous tumors, inflammatory and neuro-degenerative diseases in both humans and animals.

Employees

Sector

Pharmaceuticals

Calendar

04-30 Earnings release - Annual 2026

More about the company

Quotes

Date	Price	Change	Volume
16/10/26	€0.5490	-0.36%	26,598
15/10/26	€0.5510	-1.61%	345,166
14/10/26	€0.5600	-3.45%	154,939
13/10/26	€0.5800	+5.65%	419,375
12/10/26	€0.5490	+4.77%	177,933

Real-time Euronext Paris

More quotes

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - AB Science

Company calendar

Real-time Euronext Paris 15:11:40 16/10/2026 HKT			5-day change	1st Jan Change
0.5490 ^EUR	-0.36%		+4.77%	-64.26%

09-11	Certain Ordinary Shares of AB Science S.A. are subject to a Lock-Up Agreement Ending on 11-SEP-2026.	CI
08-17	AB Science completes settlement and delivery of its private placement

Market Cap	44.09M 49.39M 40.98M 37.27M 70.12M 4.68B 71.39M 492M 193M 2.44B 185M 181M 7.81B	P/E 2024	-5.88x	P/E 2025	-51.2x
Enterprise Value	53.35M 59.77M 49.58M 45.1M 84.85M 5.66B 86.38M 596M 233M 2.95B 224M 220M 9.45B	EV / Sales 2024	63.5x	EV / Sales 2025	103x
Free-Float	72.33%	Yield 2024 *	-	Yield 2025	-

Markets		Quality
Euronext Paris	AB	Real-time
CBOE	ABp	Real-time
London S.E.	0Q77	Delayed
Tradegate	A8D	Real-time
Deutsche Boerse AG	A8D	Delayed
CBOE	0Q77	Real-time
Börse Stuttgart	A8D	Delayed
Boerse Muenchen	A8D	Real-time

09-11	Certain Ordinary Shares of AB Science S.A. are subject to a Lock-Up Agreement Ending on 11-SEP-2026.	CI
08-17	AB Science completes settlement and delivery of its private placement
08-10	AB Science Wraps Up EUR14 Million Private Placements	MT
08-10	AB Science raises €14.2m
07-13	AB Science to Discontinue Three Masitinib-related Clinical Studies	MT
07-11	AB Science streamlines its portfolio and refocuses on two molecules
07-10	AB Science SA Provides Update on Clinical Program, Suspends Non-Priority Clinical Trials and Focuses on Ab8939 and Masitinib Programs	CI
07-08	Stéphane Ledermann takes the helm at AB Science as CEO
07-07	AB Science S.A. Announces Board Changes	CI
07-07	AB Science S.A. Announces CEO Changes	CI
07-03	AB Science S.A. announced that it has received $2.01616 million in funding	CI
07-01	AB Science, successful private placement
07-01	AB Science S.A. announced that it has received ?2.294 million in funding	CI

AB Science Stock

Stocks

AB

FR0010557264

Pharmaceuticals

Valuation: AB Science

Chart: AB Science

Latest news: AB Science

Last Transcript: AB Science

Press Releases: AB Science

News in other languages: AB Science

Quotes and Performance

Price Extremes

Managers and Directors: AB Science

Latest insider transactions

Specialty & Advanced Pharmaceuticals

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

10-13	AB Science will hold a web conference on Wednesday, October 14, 2026, from 6:00 p.m. to 7:30 p.m.	GL
10-10	AB Science : Revenues for the first half of 2026 and update on AB Science’s activities	PU
10-10	AB Science today reports its revenues for the first half of 2026 and provides an update on its activities	GL
09-29	AB Science provides an update on its development plan and financial calendar following a sponsor Good Clinical Practice inspection	GL
08-17	AB Science announces the successful settlement and delivery of securities issued as part of its €14.2 million private placement announced on August 10, 2026	GL

10-13	AB Science tiendra une web conférence le mercredi 14 octobre 2026 de 18h à 19h30
10-12	Bourse : LVMH en piste ce soir, Stellantis sort une 2CV, NVidia et Amazon s'offrent des garanties
10-12	La Bourse se découvre une passion pour le cocktail taux-croissance
10-10	AB Science annonce aujourd’hui ses résultats financiers semestriels au 30 juin 2026 et présente un point sur ses activités
10-09	Bourse : ça bouge chez Saint-Laurent (Kering) et BNP Paribas, SpaceX s'attaque aux opérateurs mobiles

1 day	-0.36%
1 week	+4.77%
Current month	-6.95%
1 month	-22.57%
3 months	-11.17%
6 months	-54.02%
Current year	-64.26%

1 week	0.53	0.6
1 month	0.51	0.73
Current year	0.5	1.61
1 year	0.5	1.61
3 years	0.5	4.46
5 years	0.5	13.76
10 years	0.5	21.75

Manager	Title	Age	Since
Stéphane Ledermann CEO	Chief Executive Officer	-	07/07/2026
Laurent Guy DFI	Director of Finance/CFO	-	20/11/2009
Christian Fassotte CTO	Chief Tech/Sci/R&D Officer	-	01/04/2018

Director	Title	Age	Since
Alain Moussy CHM	Chairman	-	11/07/2001
Stéphane Ledermann CHM	Chairman	-	07/07/2026
Patrick Moussy BRD	Director/Board Member	-	20/09/2011

Date	Insider	Type	Main position	Quantity	% Market Cap.
20/5/26	Alain Moussy	Sell	Chief Executive Officer	-573	0.0009%
9/2/21	Jean-Pierre Kinet	Sell	Founder	14,525	0.0315%
2/2/21	Jean-Pierre Kinet	Sell	Founder	76,104	0.1652%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AB SCIENCE	-0.36%	+4.77%	-61.17%	-78.88%	49.39M
ELI LILLY AND COMPANY	+3.55%	+7.01%	+51.42%	+105.45%	1,116B
JOHNSON & JOHNSON	-0.25%	-1.25%	+32.49%	+61.48%	610B
ABBVIE INC.	-0.03%	+4.03%	+25.28%	+91.54%	501B
MERCK & CO., INC.	-1.48%	+1.97%	+72.62%	+39.59%	358B
ROCHE HOLDING AG	-0.87%	+7.66%	+33.65%	+48.87%	366B
NOVARTIS AG	-1.05%	+6.95%	+21.01%	+43.85%	288B
ASTRAZENECA PLC	-1.31%	+6.78%	+0.43%	+15.71%	261B
AMGEN INC.	+1.86%	+6.53%	+45.98%	+52.77%	235B
GILEAD SCIENCES, INC.	+2.49%	+6.98%	+33.03%	+102.67%	195B
Average	+0.32%	+5.44%	+25.47%	+48.31%	392.98B
Weighted average by Cap.	+0.90%	+4.93%	+38.57%	+71.82%

	2024	2025
Net sales	1.07M 1.2M 996K 906K 1.71M 114M 1.74M 11.97M 4.68M 59.35M 4.51M 4.41M 190M	1.17M 1.32M 1.09M 993K 1.87M 125M 1.9M 13.11M 5.13M 65M 4.94M 4.83M 208M
Net income	-7.83M -8.77M -7.28M -6.62M -12.46M -831M -12.68M -87.43M -34.21M -434M -32.92M -32.23M -1.39B	-1.56M -1.74M -1.45M -1.32M -2.48M -165M -2.52M -17.38M -6.8M -86.2M -6.55M -6.41M -276M
Net Debt	10.48M 11.75M 9.74M 8.86M 16.68M 1.11B 16.98M 117M 45.8M 580M 44.08M 43.14M 1.86B	9.26M 10.38M 8.61M 7.83M 14.73M 983M 15M 103M 40.45M 513M 38.94M 38.11M 1.64B